COVID-19 Impact on Global Targeted Drugs for NSCLC Market Size, Status and Forecast 2020-2026

July 2020 | 153 pages | ID: C693BF5793B3EN
QYResearch

Abstracts

This report focuses on the global Targeted Drugs for NSCLC status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Targeted Drugs for NSCLC development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Allergan
• Amgen
• ARIAD Pharmaceuticals (Takeda)
• Beacon Pharma Limited
• BeiGene
• Biocon
• Boehringer-Ingelheim
• Celgene Corporation
• Drug International Limted
• Fujifilm Kyowa Kirin Biologics
• Genvio Pharma Limited
• Hetero Drugs
• ImClone Systems ?(Eli Lilly)
• Incepta Pharmaceuticals
• Mylan
• Novartis
• Pfizer
• Reliance Lifesciences
• Roche
• AstraZeneca
• Cipla
• Teva
• OSI Pharmaceuticals
• Glenmark Pharmaceuticals
• Natco Pharma

Market segment by Type, the product can be split into

• Target EGFR
• Target ALK
• Target HER2
• Target ROS1
• Target BRAF
• Target MEK
• Target VEGFR2
• Target VEGF
• Target MET

Market segment by Application, split into

• Squamous Cell Carcinoma of NSCLC
• Adenocarcinoma of NSCLC
• Large Cell Carcinoma of NSCLC

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Targeted Drugs for NSCLC status, future forecast, growth opportunity, key market and key players.
• To present the Targeted Drugs for NSCLC development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Targeted Drugs for NSCLC are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Targeted Drugs for NSCLC Revenue
1.4 Market Analysis by Type
  1.4.1 Global Targeted Drugs for NSCLC Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Target EGFR
  1.4.3 Target ALK
  1.4.4 Target HER2
  1.4.5 Target ROS1
  1.4.6 Target BRAF
  1.4.7 Target MEK
  1.4.8 Target VEGFR2
  1.4.9 Target VEGF
  1.4.10 Target MET
1.5 Market by Application
  1.5.1 Global Targeted Drugs for NSCLC Market Share by Application: 2020 VS 2026
  1.5.2 Squamous Cell Carcinoma of NSCLC
  1.5.3 Adenocarcinoma of NSCLC
  1.5.4 Large Cell Carcinoma of NSCLC
1.6 Coronavirus Disease 2019 (Covid-19): Targeted Drugs for NSCLC Industry Impact
  1.6.1 How the Covid-19 is Affecting the Targeted Drugs for NSCLC Industry
    1.6.1.1 Targeted Drugs for NSCLC Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Targeted Drugs for NSCLC Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Targeted Drugs for NSCLC Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Targeted Drugs for NSCLC Market Perspective (2015-2026)
2.2 Targeted Drugs for NSCLC Growth Trends by Regions
  2.2.1 Targeted Drugs for NSCLC Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Targeted Drugs for NSCLC Historic Market Share by Regions (2015-2020)
  2.2.3 Targeted Drugs for NSCLC Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Targeted Drugs for NSCLC Market Growth Strategy
  2.3.6 Primary Interviews with Key Targeted Drugs for NSCLC Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Targeted Drugs for NSCLC Players by Market Size
  3.1.1 Global Top Targeted Drugs for NSCLC Players by Revenue (2015-2020)
  3.1.2 Global Targeted Drugs for NSCLC Revenue Market Share by Players (2015-2020)
  3.1.3 Global Targeted Drugs for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Targeted Drugs for NSCLC Market Concentration Ratio
  3.2.1 Global Targeted Drugs for NSCLC Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Targeted Drugs for NSCLC Revenue in 2019
3.3 Targeted Drugs for NSCLC Key Players Head office and Area Served
3.4 Key Players Targeted Drugs for NSCLC Product Solution and Service
3.5 Date of Enter into Targeted Drugs for NSCLC Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Targeted Drugs for NSCLC Historic Market Size by Type (2015-2020)
4.2 Global Targeted Drugs for NSCLC Forecasted Market Size by Type (2021-2026)

5 TARGETED DRUGS FOR NSCLC BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Targeted Drugs for NSCLC Market Size by Application (2015-2020)
5.2 Global Targeted Drugs for NSCLC Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Targeted Drugs for NSCLC Market Size (2015-2020)
6.2 Targeted Drugs for NSCLC Key Players in North America (2019-2020)
6.3 North America Targeted Drugs for NSCLC Market Size by Type (2015-2020)
6.4 North America Targeted Drugs for NSCLC Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Targeted Drugs for NSCLC Market Size (2015-2020)
7.2 Targeted Drugs for NSCLC Key Players in Europe (2019-2020)
7.3 Europe Targeted Drugs for NSCLC Market Size by Type (2015-2020)
7.4 Europe Targeted Drugs for NSCLC Market Size by Application (2015-2020)

8 CHINA

8.1 China Targeted Drugs for NSCLC Market Size (2015-2020)
8.2 Targeted Drugs for NSCLC Key Players in China (2019-2020)
8.3 China Targeted Drugs for NSCLC Market Size by Type (2015-2020)
8.4 China Targeted Drugs for NSCLC Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Targeted Drugs for NSCLC Market Size (2015-2020)
9.2 Targeted Drugs for NSCLC Key Players in Japan (2019-2020)
9.3 Japan Targeted Drugs for NSCLC Market Size by Type (2015-2020)
9.4 Japan Targeted Drugs for NSCLC Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Targeted Drugs for NSCLC Market Size (2015-2020)
10.2 Targeted Drugs for NSCLC Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Targeted Drugs for NSCLC Market Size by Type (2015-2020)
10.4 Southeast Asia Targeted Drugs for NSCLC Market Size by Application (2015-2020)

11 INDIA

11.1 India Targeted Drugs for NSCLC Market Size (2015-2020)
11.2 Targeted Drugs for NSCLC Key Players in India (2019-2020)
11.3 India Targeted Drugs for NSCLC Market Size by Type (2015-2020)
11.4 India Targeted Drugs for NSCLC Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Targeted Drugs for NSCLC Market Size (2015-2020)
12.2 Targeted Drugs for NSCLC Key Players in Central & South America (2019-2020)
12.3 Central & South America Targeted Drugs for NSCLC Market Size by Type (2015-2020)
12.4 Central & South America Targeted Drugs for NSCLC Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Allergan
  13.1.1 Allergan Company Details
  13.1.2 Allergan Business Overview and Its Total Revenue
  13.1.3 Allergan Targeted Drugs for NSCLC Introduction
  13.1.4 Allergan Revenue in Targeted Drugs for NSCLC Business (2015-2020))
  13.1.5 Allergan Recent Development
13.2 Amgen
  13.2.1 Amgen Company Details
  13.2.2 Amgen Business Overview and Its Total Revenue
  13.2.3 Amgen Targeted Drugs for NSCLC Introduction
  13.2.4 Amgen Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  13.2.5 Amgen Recent Development
13.3 ARIAD Pharmaceuticals (Takeda)
  13.3.1 ARIAD Pharmaceuticals (Takeda) Company Details
  13.3.2 ARIAD Pharmaceuticals (Takeda) Business Overview and Its Total Revenue
  13.3.3 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Introduction
  13.3.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  13.3.5 ARIAD Pharmaceuticals (Takeda) Recent Development
13.4 Beacon Pharma Limited
  13.4.1 Beacon Pharma Limited Company Details
  13.4.2 Beacon Pharma Limited Business Overview and Its Total Revenue
  13.4.3 Beacon Pharma Limited Targeted Drugs for NSCLC Introduction
  13.4.4 Beacon Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  13.4.5 Beacon Pharma Limited Recent Development
13.5 BeiGene
  13.5.1 BeiGene Company Details
  13.5.2 BeiGene Business Overview and Its Total Revenue
  13.5.3 BeiGene Targeted Drugs for NSCLC Introduction
  13.5.4 BeiGene Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  13.5.5 BeiGene Recent Development
13.6 Biocon
  13.6.1 Biocon Company Details
  13.6.2 Biocon Business Overview and Its Total Revenue
  13.6.3 Biocon Targeted Drugs for NSCLC Introduction
  13.6.4 Biocon Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  13.6.5 Biocon Recent Development
13.7 Boehringer-Ingelheim
  13.7.1 Boehringer-Ingelheim Company Details
  13.7.2 Boehringer-Ingelheim Business Overview and Its Total Revenue
  13.7.3 Boehringer-Ingelheim Targeted Drugs for NSCLC Introduction
  13.7.4 Boehringer-Ingelheim Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  13.7.5 Boehringer-Ingelheim Recent Development
13.8 Celgene Corporation
  13.8.1 Celgene Corporation Company Details
  13.8.2 Celgene Corporation Business Overview and Its Total Revenue
  13.8.3 Celgene Corporation Targeted Drugs for NSCLC Introduction
  13.8.4 Celgene Corporation Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  13.8.5 Celgene Corporation Recent Development
13.9 Drug International Limted
  13.9.1 Drug International Limted Company Details
  13.9.2 Drug International Limted Business Overview and Its Total Revenue
  13.9.3 Drug International Limted Targeted Drugs for NSCLC Introduction
  13.9.4 Drug International Limted Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  13.9.5 Drug International Limted Recent Development
13.10 Fujifilm Kyowa Kirin Biologics
  13.10.1 Fujifilm Kyowa Kirin Biologics Company Details
  13.10.2 Fujifilm Kyowa Kirin Biologics Business Overview and Its Total Revenue
  13.10.3 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Introduction
  13.10.4 Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  13.10.5 Fujifilm Kyowa Kirin Biologics Recent Development
13.11 Genvio Pharma Limited
  10.11.1 Genvio Pharma Limited Company Details
  10.11.2 Genvio Pharma Limited Business Overview and Its Total Revenue
  10.11.3 Genvio Pharma Limited Targeted Drugs for NSCLC Introduction
  10.11.4 Genvio Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  10.11.5 Genvio Pharma Limited Recent Development
13.12 Hetero Drugs
  10.12.1 Hetero Drugs Company Details
  10.12.2 Hetero Drugs Business Overview and Its Total Revenue
  10.12.3 Hetero Drugs Targeted Drugs for NSCLC Introduction
  10.12.4 Hetero Drugs Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  10.12.5 Hetero Drugs Recent Development
13.13 ImClone Systems ?(Eli Lilly)
  10.13.1 ImClone Systems ?(Eli Lilly) Company Details
  10.13.2 ImClone Systems ?(Eli Lilly) Business Overview and Its Total Revenue
  10.13.3 ImClone Systems ?(Eli Lilly) Targeted Drugs for NSCLC Introduction
  10.13.4 ImClone Systems ?(Eli Lilly) Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  10.13.5 ImClone Systems ?(Eli Lilly) Recent Development
13.14 Incepta Pharmaceuticals
  10.14.1 Incepta Pharmaceuticals Company Details
  10.14.2 Incepta Pharmaceuticals Business Overview and Its Total Revenue
  10.14.3 Incepta Pharmaceuticals Targeted Drugs for NSCLC Introduction
  10.14.4 Incepta Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  10.14.5 Incepta Pharmaceuticals Recent Development
13.15 Mylan
  10.15.1 Mylan Company Details
  10.15.2 Mylan Business Overview and Its Total Revenue
  10.15.3 Mylan Targeted Drugs for NSCLC Introduction
  10.15.4 Mylan Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  10.15.5 Mylan Recent Development
13.16 Novartis
  10.16.1 Novartis Company Details
  10.16.2 Novartis Business Overview and Its Total Revenue
  10.16.3 Novartis Targeted Drugs for NSCLC Introduction
  10.16.4 Novartis Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  10.16.5 Novartis Recent Development
13.17 Pfizer
  10.17.1 Pfizer Company Details
  10.17.2 Pfizer Business Overview and Its Total Revenue
  10.17.3 Pfizer Targeted Drugs for NSCLC Introduction
  10.17.4 Pfizer Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  10.17.5 Pfizer Recent Development
13.18 Reliance Lifesciences
  10.18.1 Reliance Lifesciences Company Details
  10.18.2 Reliance Lifesciences Business Overview and Its Total Revenue
  10.18.3 Reliance Lifesciences Targeted Drugs for NSCLC Introduction
  10.18.4 Reliance Lifesciences Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  10.18.5 Reliance Lifesciences Recent Development
13.19 Roche
  10.19.1 Roche Company Details
  10.19.2 Roche Business Overview and Its Total Revenue
  10.19.3 Roche Targeted Drugs for NSCLC Introduction
  10.19.4 Roche Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  10.19.5 Roche Recent Development
13.20 AstraZeneca
  10.20.1 AstraZeneca Company Details
  10.20.2 AstraZeneca Business Overview and Its Total Revenue
  10.20.3 AstraZeneca Targeted Drugs for NSCLC Introduction
  10.20.4 AstraZeneca Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  10.20.5 AstraZeneca Recent Development
13.21 Cipla
  10.21.1 Cipla Company Details
  10.21.2 Cipla Business Overview and Its Total Revenue
  10.21.3 Cipla Targeted Drugs for NSCLC Introduction
  10.21.4 Cipla Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  10.21.5 Cipla Recent Development
13.22 Teva
  10.22.1 Teva Company Details
  10.22.2 Teva Business Overview and Its Total Revenue
  10.22.3 Teva Targeted Drugs for NSCLC Introduction
  10.22.4 Teva Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  10.22.5 Teva Recent Development
13.23 OSI Pharmaceuticals
  10.23.1 OSI Pharmaceuticals Company Details
  10.23.2 OSI Pharmaceuticals Business Overview and Its Total Revenue
  10.23.3 OSI Pharmaceuticals Targeted Drugs for NSCLC Introduction
  10.23.4 OSI Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  10.23.5 OSI Pharmaceuticals Recent Development
13.24 Glenmark Pharmaceuticals
  10.24.1 Glenmark Pharmaceuticals Company Details
  10.24.2 Glenmark Pharmaceuticals Business Overview and Its Total Revenue
  10.24.3 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Introduction
  10.24.4 Glenmark Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  10.24.5 Glenmark Pharmaceuticals Recent Development
13.25 Natco Pharma
  10.25.1 Natco Pharma Company Details
  10.25.2 Natco Pharma Business Overview and Its Total Revenue
  10.25.3 Natco Pharma Targeted Drugs for NSCLC Introduction
  10.25.4 Natco Pharma Revenue in Targeted Drugs for NSCLC Business (2015-2020)
  10.25.5 Natco Pharma Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Targeted Drugs for NSCLC Key Market Segments
Table 2. Key Players Covered: Ranking by Targeted Drugs for NSCLC Revenue
Table 3. Ranking of Global Top Targeted Drugs for NSCLC Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Targeted Drugs for NSCLC Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Target EGFR
Table 6. Key Players of Target ALK
Table 7. Key Players of Target HER2
Table 8. Key Players of Target ROS1
Table 9. Key Players of Target BRAF
Table 10. Key Players of Target MEK
Table 11. Key Players of Target VEGFR2
Table 12. Key Players of Target VEGF
Table 13. Key Players of Target MET
Table 14. COVID-19 Impact Global Market: (Four Targeted Drugs for NSCLC Market Size Forecast Scenarios)
Table 15. Opportunities and Trends for Targeted Drugs for NSCLC Players in the COVID-19 Landscape
Table 16. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 17. Key Regions/Countries Measures against Covid-19 Impact
Table 18. Proposal for Targeted Drugs for NSCLC Players to Combat Covid-19 Impact
Table 19. Global Targeted Drugs for NSCLC Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 20. Global Targeted Drugs for NSCLC Market Size by Regions (US$ Million): 2020 VS 2026
Table 21. Global Targeted Drugs for NSCLC Market Size by Regions (2015-2020) (US$ Million)
Table 22. Global Targeted Drugs for NSCLC Market Share by Regions (2015-2020)
Table 23. Global Targeted Drugs for NSCLC Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 24. Global Targeted Drugs for NSCLC Market Share by Regions (2021-2026)
Table 25. Market Top Trends
Table 26. Key Drivers: Impact Analysis
Table 27. Key Challenges
Table 28. Targeted Drugs for NSCLC Market Growth Strategy
Table 29. Main Points Interviewed from Key Targeted Drugs for NSCLC Players
Table 30. Global Targeted Drugs for NSCLC Revenue by Players (2015-2020) (Million US$)
Table 31. Global Targeted Drugs for NSCLC Market Share by Players (2015-2020)
Table 32. Global Top Targeted Drugs for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drugs for NSCLC as of 2019)
Table 33. Global Targeted Drugs for NSCLC by Players Market Concentration Ratio (CR5 and HHI)
Table 34. Key Players Headquarters and Area Served
Table 35. Key Players Targeted Drugs for NSCLC Product Solution and Service
Table 36. Date of Enter into Targeted Drugs for NSCLC Market
Table 37. Mergers & Acquisitions, Expansion Plans
Table 38. Global Targeted Drugs for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 39. Global Targeted Drugs for NSCLC Market Size Share by Type (2015-2020)
Table 40. Global Targeted Drugs for NSCLC Revenue Market Share by Type (2021-2026)
Table 41. Global Targeted Drugs for NSCLC Market Size Share by Application (2015-2020)
Table 42. Global Targeted Drugs for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 43. Global Targeted Drugs for NSCLC Market Size Share by Application (2021-2026)
Table 44. North America Key Players Targeted Drugs for NSCLC Revenue (2019-2020) (Million US$)
Table 45. North America Key Players Targeted Drugs for NSCLC Market Share (2019-2020)
Table 46. North America Targeted Drugs for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 47. North America Targeted Drugs for NSCLC Market Share by Type (2015-2020)
Table 48. North America Targeted Drugs for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 49. North America Targeted Drugs for NSCLC Market Share by Application (2015-2020)
Table 50. Europe Key Players Targeted Drugs for NSCLC Revenue (2019-2020) (Million US$)
Table 51. Europe Key Players Targeted Drugs for NSCLC Market Share (2019-2020)
Table 52. Europe Targeted Drugs for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 53. Europe Targeted Drugs for NSCLC Market Share by Type (2015-2020)
Table 54. Europe Targeted Drugs for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 55. Europe Targeted Drugs for NSCLC Market Share by Application (2015-2020)
Table 56. China Key Players Targeted Drugs for NSCLC Revenue (2019-2020) (Million US$)
Table 57. China Key Players Targeted Drugs for NSCLC Market Share (2019-2020)
Table 58. China Targeted Drugs for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 59. China Targeted Drugs for NSCLC Market Share by Type (2015-2020)
Table 60. China Targeted Drugs for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 61. China Targeted Drugs for NSCLC Market Share by Application (2015-2020)
Table 62. Japan Key Players Targeted Drugs for NSCLC Revenue (2019-2020) (Million US$)
Table 63. Japan Key Players Targeted Drugs for NSCLC Market Share (2019-2020)
Table 64. Japan Targeted Drugs for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 65. Japan Targeted Drugs for NSCLC Market Share by Type (2015-2020)
Table 66. Japan Targeted Drugs for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 67. Japan Targeted Drugs for NSCLC Market Share by Application (2015-2020)
Table 68. Southeast Asia Key Players Targeted Drugs for NSCLC Revenue (2019-2020) (Million US$)
Table 69. Southeast Asia Key Players Targeted Drugs for NSCLC Market Share (2019-2020)
Table 70. Southeast Asia Targeted Drugs for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 71. Southeast Asia Targeted Drugs for NSCLC Market Share by Type (2015-2020)
Table 72. Southeast Asia Targeted Drugs for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 73. Southeast Asia Targeted Drugs for NSCLC Market Share by Application (2015-2020)
Table 74. India Key Players Targeted Drugs for NSCLC Revenue (2019-2020) (Million US$)
Table 75. India Key Players Targeted Drugs for NSCLC Market Share (2019-2020)
Table 76. India Targeted Drugs for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 77. India Targeted Drugs for NSCLC Market Share by Type (2015-2020)
Table 78. India Targeted Drugs for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 79. India Targeted Drugs for NSCLC Market Share by Application (2015-2020)
Table 80. Central & South America Key Players Targeted Drugs for NSCLC Revenue (2019-2020) (Million US$)
Table 81. Central & South America Key Players Targeted Drugs for NSCLC Market Share (2019-2020)
Table 82. Central & South America Targeted Drugs for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 83. Central & South America Targeted Drugs for NSCLC Market Share by Type (2015-2020)
Table 84. Central & South America Targeted Drugs for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 85. Central & South America Targeted Drugs for NSCLC Market Share by Application (2015-2020)
Table 86. Allergan Company Details
Table 87. Allergan Business Overview
Table 88. Allergan Product
Table 89. Allergan Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 90. Allergan Recent Development
Table 91. Amgen Company Details
Table 92. Amgen Business Overview
Table 93. Amgen Product
Table 94. Amgen Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 95. Amgen Recent Development
Table 96. ARIAD Pharmaceuticals (Takeda) Company Details
Table 97. ARIAD Pharmaceuticals (Takeda) Business Overview
Table 98. ARIAD Pharmaceuticals (Takeda) Product
Table 99. ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 100. ARIAD Pharmaceuticals (Takeda) Recent Development
Table 101. Beacon Pharma Limited Company Details
Table 102. Beacon Pharma Limited Business Overview
Table 103. Beacon Pharma Limited Product
Table 104. Beacon Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 105. Beacon Pharma Limited Recent Development
Table 106. BeiGene Company Details
Table 107. BeiGene Business Overview
Table 108. BeiGene Product
Table 109. BeiGene Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 110. BeiGene Recent Development
Table 111. Biocon Company Details
Table 112. Biocon Business Overview
Table 113. Biocon Product
Table 114. Biocon Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 115. Biocon Recent Development
Table 116. Boehringer-Ingelheim Company Details
Table 117. Boehringer-Ingelheim Business Overview
Table 118. Boehringer-Ingelheim Product
Table 119. Boehringer-Ingelheim Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 120. Boehringer-Ingelheim Recent Development
Table 121. Celgene Corporation Business Overview
Table 122. Celgene Corporation Product
Table 123. Celgene Corporation Company Details
Table 124. Celgene Corporation Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 125. Celgene Corporation Recent Development
Table 126. Drug International Limted Company Details
Table 127. Drug International Limted Business Overview
Table 128. Drug International Limted Product
Table 129. Drug International Limted Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 130. Drug International Limted Recent Development
Table 131. Fujifilm Kyowa Kirin Biologics Company Details
Table 132. Fujifilm Kyowa Kirin Biologics Business Overview
Table 133. Fujifilm Kyowa Kirin Biologics Product
Table 134. Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 135. Fujifilm Kyowa Kirin Biologics Recent Development
Table 136. Genvio Pharma Limited Company Details
Table 137. Genvio Pharma Limited Business Overview
Table 138. Genvio Pharma Limited Product
Table 139. Genvio Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 140. Genvio Pharma Limited Recent Development
Table 141. Hetero Drugs Company Details
Table 142. Hetero Drugs Business Overview
Table 143. Hetero Drugs Product
Table 144. Hetero Drugs Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 145. Hetero Drugs Recent Development
Table 146. ImClone Systems ?(Eli Lilly) Company Details
Table 147. ImClone Systems ?(Eli Lilly) Business Overview
Table 148. ImClone Systems ?(Eli Lilly) Product
Table 149. ImClone Systems ?(Eli Lilly) Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 150. ImClone Systems ?(Eli Lilly) Recent Development
Table 151. Incepta Pharmaceuticals Company Details
Table 152. Incepta Pharmaceuticals Business Overview
Table 153. Incepta Pharmaceuticals Product
Table 154. Incepta Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 155. Incepta Pharmaceuticals Recent Development
Table 156. Mylan Company Details
Table 157. Mylan Business Overview
Table 158. Mylan Product
Table 159. Mylan Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 160. Mylan Recent Development
Table 161. Novartis Company Details
Table 162. Novartis Business Overview
Table 163. Novartis Product
Table 164. Novartis Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 165. Novartis Recent Development
Table 166. Pfizer Company Details
Table 167. Pfizer Business Overview
Table 168. Pfizer Product
Table 169. Pfizer Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 170. Pfizer Recent Development
Table 171. Reliance Lifesciences Company Details
Table 172. Reliance Lifesciences Business Overview
Table 173. Reliance Lifesciences Product
Table 174. Reliance Lifesciences Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 175. Reliance Lifesciences Recent Development
Table 176. Roche Company Details
Table 177. Roche Business Overview
Table 178. Roche Product
Table 179. Roche Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 180. Roche Recent Development
Table 181. AstraZeneca Company Details
Table 182. AstraZeneca Business Overview
Table 183. AstraZeneca Product
Table 184. AstraZeneca Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 185. AstraZeneca Recent Development
Table 186. Cipla Company Details
Table 187. Cipla Business Overview
Table 188. Cipla Product
Table 189. Cipla Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 190. Cipla Recent Development
Table 191. Teva Company Details
Table 192. Teva Business Overview
Table 193. Teva Product
Table 194. Teva Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 195. Teva Recent Development
Table 196. OSI Pharmaceuticals Company Details
Table 197. OSI Pharmaceuticals Business Overview
Table 198. OSI Pharmaceuticals Product
Table 199. OSI Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 200. OSI Pharmaceuticals Recent Development
Table 201. Glenmark Pharmaceuticals Company Details
Table 202. Glenmark Pharmaceuticals Business Overview
Table 203. Glenmark Pharmaceuticals Product
Table 204. Glenmark Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 205. Glenmark Pharmaceuticals Recent Development
Table 206. Natco Pharma Company Details
Table 207. Natco Pharma Business Overview
Table 208. Natco Pharma Product
Table 209. Natco Pharma Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US$)
Table 210. Natco Pharma Recent Development
Table 211. Research Programs/Design for This Report
Table 212. Key Data Information from Secondary Sources
Table 213. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Targeted Drugs for NSCLC Market Share by Type: 2020 VS 2026
Figure 2. Target EGFR Features
Figure 3. Target ALK Features
Figure 4. Target HER2 Features
Figure 5. Target ROS1 Features
Figure 6. Target BRAF Features
Figure 7. Target MEK Features
Figure 8. Target VEGFR2 Features
Figure 9. Target VEGF Features
Figure 10. Target MET Features
Figure 11. Global Targeted Drugs for NSCLC Market Share by Application: 2020 VS 2026
Figure 12. Squamous Cell Carcinoma of NSCLC Case Studies
Figure 13. Adenocarcinoma of NSCLC Case Studies
Figure 14. Large Cell Carcinoma of NSCLC Case Studies
Figure 15. Targeted Drugs for NSCLC Report Years Considered
Figure 16. Global Targeted Drugs for NSCLC Market Size YoY Growth 2015-2026 (US$ Million)
Figure 17. Global Targeted Drugs for NSCLC Market Share by Regions: 2020 VS 2026
Figure 18. Global Targeted Drugs for NSCLC Market Share by Regions (2021-2026)
Figure 19. Porter's Five Forces Analysis
Figure 20. Global Targeted Drugs for NSCLC Market Share by Players in 2019
Figure 21. Global Top Targeted Drugs for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drugs for NSCLC as of 2019
Figure 22. The Top 10 and 5 Players Market Share by Targeted Drugs for NSCLC Revenue in 2019
Figure 23. North America Targeted Drugs for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Europe Targeted Drugs for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. China Targeted Drugs for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Japan Targeted Drugs for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Southeast Asia Targeted Drugs for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. India Targeted Drugs for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Central & South America Targeted Drugs for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 30. Allergan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Allergan Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)
Figure 32. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Amgen Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)
Figure 34. ARIAD Pharmaceuticals (Takeda) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. ARIAD Pharmaceuticals (Takeda) Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)
Figure 36. Beacon Pharma Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Beacon Pharma Limited Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)
Figure 38. BeiGene Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. BeiGene Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)
Figure 40. Biocon Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Biocon Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)
Figure 42. Boehringer-Ingelheim Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Boehringer-Ingelheim Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)
Figure 44. Celgene Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Celgene Corporation Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)
Figure 46. Drug International Limted Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Drug International Limted Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)
Figure 48. Fujifilm Kyowa Kirin Biologics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Fujifilm Kyowa Kirin Biologics Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)
Figure 50. Genvio Pharma Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Genvio Pharma Limited Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)
Figure 52. Hetero Drugs Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Hetero Drugs Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)
Figure 54. ImClone Systems ?(Eli Lilly) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. ImClone Systems ?(Eli Lilly) Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)
Figure 56. Incepta Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Incepta Pharmaceuticals Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)
Figure 58. Mylan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Mylan Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)
Figure 60. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Novartis Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)
Figure 62. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Pfizer Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)
Figure 64. Reliance Lifesciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. Reliance Lifesciences Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)
Figure 66. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 67. Roche Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)
Figure 68. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 69. AstraZeneca Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed